共 325 条
[1]
Hoffman EP(2014)Exon-skipping therapy: a roadblock, detour, or bump in the road? Sci Transl Med 6 230fs214-2686
[2]
McNally EM(2007)Local dystrophin restoration with antisense oligonucleotide PRO051 N Engl J Med 357 2677-928
[3]
van Deutekom JC(2009)Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study Lancet Neurol 8 918-996
[4]
Janson AA(2014)Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study Lancet Neurol 13 987-1522
[5]
Ginjaar IB(2011)Systemic administration of PRO051 in Duchenne's muscular dystrophy New Engl J Med 364 1513-26
[6]
Frankhuizen WS(2015)The emperor's new dystrophin: finding sense in the noise Trends Mol Med 21 417-605
[7]
Aartsma-Rus A(2011)Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Lancet 378 595-647
[8]
Bremmer-Bout M(2013)Eteplirsen for the treatment of Duchenne muscular dystrophy Ann Neurol 74 637-487
[9]
den Dunnen JT(2014)Ataluren treatment of patients with nonsense mutation dystrophinopathy Muscle Nerve 50 477-239
[10]
Koop K(2013)Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy PLoS One 8 e152-329